SelectQuote, Inc. 8-K

What Happened
SelectQuote, Inc. announced it received a notice from the New York Stock Exchange on March 19, 2026 that it is not in compliance with Section 802.01C because the average closing price of its common stock was below $1.00 over a consecutive 30 trading‑day period. The company filed an 8‑K and issued a press release on March 25, 2026, and has informed the NYSE it intends to cure the deficiency.

Key Details

• NYSE notice received: March 19, 2026, citing non‑compliance with the $1.00 minimum average closing price rule (Section 802.01C).
• Cure period: Six months from receipt of the notice; compliance can be regained if on the last trading day of any calendar month during the period the stock has a closing price ≥ $1.00 and a 30‑trading‑day average ≥ $1.00.
• Alternate cure: If a stockholder‑approved action is required, the price condition is met if the stock promptly rises above $1.00 and stays above that level for at least 30 trading days following the action.
• Trading status: The company’s common stock will remain listed and traded on the NYSE during the cure period, subject to other listing standards.
• The company issued a press release on March 25, 2026 (Exhibit 99.1) and said it will monitor the stock and consider alternatives to regain compliance.

Why It Matters
For investors, the NYSE notice signals a short‑term listing risk tied to the company’s low share price. While the stock remains listed during the six‑month cure period, failure to regain compliance could lead to delisting, which can reduce liquidity and shareholder value. The company’s statement is procedural—SelectQuote intends to pursue available remedies—but investors should monitor share‑price trends, company updates, and any proposed corrective actions.